Overview Dividends

(CGEM) Cullinan Oncology - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2300311063

Zipalertinib, CLN-978, CLN-619, CLN-049, CLN-617

CGEM EPS (Earnings per Share)

EPS Growth (3Y CAGR): 20.03%
EPS Trend (3Y Correlation): 41.4%

CGEM Revenue

Revenue Growth (3Y CAGR): 0.00%

Description: CGEM Cullinan Oncology October 24, 2025

Cullinan Therapeutics, Inc. (NASDAQ: CGEM) is a U.S. clinical-stage biotech focused on small-molecule and antibody therapeutics for oncology and autoimmune disorders. Its lead assets include zipalertinib (Phase 3 NSCLC), CLN-978 (T-cell engager for SLE and RA), and CLN-619 (monoclonal antibody in Phase 1 for solid tumors and multiple myeloma). Additional pipelines are CLN-049 (bispecific antibody for AML/MDS and MRD-positive AML) and CLN-617 (fusion protein for solid tumors). The company collaborates with Adimab on antibody discovery and with Taiho Pharmaceutical on zipalertinib co-development. Formerly Cullinan Oncology, the firm rebranded to Cullinan Therapeutics in April 2024 and is headquartered in Cambridge, MA.

Key market-level drivers that will shape CGEM’s upside include (i) the U.S. oncology market’s projected CAGR of ~8 % through 2030, (ii) FDA’s historically higher approval rates for Phase 3 trials in NSCLC (~30 % in the last five years), and (iii) the company’s cash runway, which, according to its most recent 10-Q, was sufficient for ~12 months of operating expenses-though exact burn-rate figures are not disclosed publicly, introducing uncertainty around near-term financing needs.

If you want a data-rich, quantitative view of CGEM’s valuation and risk profile, the ValueRay analyst model provides a useful starting point for deeper research.

CGEM Stock Overview

Market Cap in USD	512m
Sub-Industry	Biotechnology
IPO / Inception	2021-01-08

CGEM Stock Ratings

Growth Rating	-70.6%
Fundamental	32.0%
Dividend Rating	-
Return 12m vs S&P 500	-61.2%
Analyst Rating	4.89 of 5

CGEM Dividends

Currently no dividends paid

CGEM Growth Ratios

Growth Correlation 3m	15.8%
Growth Correlation 12m	-81.7%
Growth Correlation 5y	-64.2%
CAGR 5y	-16.02%
CAGR/Max DD 3y (Calmar Ratio)	-0.20
CAGR/Mean DD 3y (Pain Ratio)	-0.41
Sharpe Ratio 12m	-0.74
Alpha	-56.31
Beta	-0.116
Volatility	67.18%
Current Volume	617.8k
Average Volume 20d	979.8k
Stop Loss	6.8 (-7.5%)
Signal	-0.53

Piotroski VR‑10 (Strict, 0-10) 0.0

error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM)

FCFTA -0.33 (>2.0%) and ΔFCFTA -14.35pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev)

CFO/TA -0.33 (>3.0%) and CFO -171.5m > Net Income -206.8m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 9.83 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (59.0m) change vs 12m ago 7.20% (target <= -2.0% for YES)

error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue)

Asset Turnover 0.0% (prev 0.0%; Δ 0.0pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -8.35 (EBITDA TTM -234.5m / Interest Expense TTM -28.1m) >= 6 (WARN >= 3)

Altman Z'' -20.66

(A) 0.48 = (Total Current Assets 275.9m - Total Current Liabilities 28.1m) / Total Assets 520.3m

(B) -0.94 = Retained Earnings (Balance) -486.8m / Total Assets 520.3m

(D) -17.25 = Book Value of Equity -486.2m / Total Liabilities 28.2m

Total Rating: -20.66 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 32.00

1. Piotroski 0.0pt = -5.0

2. FCF Yield -69.27% = -5.0

3. FCF Margin data missing

4. Debt/Equity 0.00 = 2.50

5. Debt/Ebitda 0.30 = 2.43

6. ROIC - WACC (= -47.12)% = -12.50

7. RoE -36.56% = -2.50

8. Revenue Trend data missing

9. EPS Trend 41.44% = 2.07

What is the price of CGEM shares?

As of November 07, 2025, the stock is trading at USD 7.35 with a total of 617,808 shares traded.
Over the past week, the price has changed by -2.78%, over one month by +25.86%, over three months by -6.73% and over the past year by -55.40%.

Is Cullinan Oncology a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Cullinan Oncology (NASDAQ:CGEM) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 32.00 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CGEM is around 5.62 USD . This means that CGEM is currently overvalued and has a potential downside of -23.54%.

Is CGEM a buy, sell or hold?

Cullinan Oncology has received a consensus analysts rating of 4.89. Therefore, it is recommended to buy CGEM.

Strong Buy: 8
Buy: 1
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the CGEM price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	26.2	256.7%
Analysts Target Price	26.2	256.7%
ValueRay Target Price	6.1	-17%

CGEM Fundamental Data Overview November 04, 2025

Market Cap USD = 511.6m (511.6m USD * 1.0 USD.USD)
P/E Forward = 6.3012
P/S = 26.8794
P/B = 0.6902
Beta = -0.116
Revenue TTM = 0.0 USD
EBIT TTM = -234.8m USD
EBITDA TTM = -234.5m USD
Long Term Debt = 1.52m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.39m USD (from shortTermDebt, last quarter)
Debt = 1.52m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -71.3m USD (from netDebt column, last quarter)
Enterprise Value = 247.6m USD (511.6m + Debt 1.52m - CCE 265.5m)
Interest Coverage Ratio = -8.35 (Ebit TTM -234.8m / Interest Expense TTM -28.1m)
FCF Yield = -69.27% (FCF TTM -171.5m / Enterprise Value 247.6m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 306.0k) / Revenue TTM)
Tobins Q-Ratio = 0.48 (Enterprise Value 247.6m / Total Assets 520.3m)
Interest Expense / Debt = 303.8% (Interest Expense 4.62m / Debt 1.52m)
Taxrate = -0.07% (negative due to tax credits) (117.0k / -167.5m)
NOPAT = -234.9m (EBIT -234.8m * (1 - -0.07%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 9.83 (Total Current Assets 275.9m / Total Current Liabilities 28.1m)
Debt / Equity = 0.00 (Debt 1.52m / totalStockholderEquity, last quarter 492.1m)
Debt / EBITDA = 0.30 (negative EBITDA) (Net Debt -71.3m / EBITDA -234.5m)
Debt / FCF = 0.42 (negative FCF - burning cash) (Net Debt -71.3m / FCF TTM -171.5m)
Total Stockholder Equity = 565.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -39.74% (Net Income -206.8m / Total Assets 520.3m)
RoE = -36.56% (Net Income TTM -206.8m / Total Stockholder Equity 565.5m)
RoCE = -41.40% (EBIT -234.8m / Capital Employed (Equity 565.5m + L.T.Debt 1.52m))
RoIC = -41.54% (negative operating profit) (NOPAT -234.9m / Invested Capital 565.5m)
WACC = 5.57% (E(511.6m)/V(513.1m) * Re(5.59%) + (debt cost/tax rate unavailable))
Discount Rate = 5.59% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 17.43%
Fair Price DCF = unknown (Cash Flow -171.5m)
EPS Correlation: 41.44 | EPS CAGR: 20.03% | SUE: 4.0 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0

Additional Sources for CGEM Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle